AU2022229597A1 - Actinohivin variant polypeptides and related methods - Google Patents

Actinohivin variant polypeptides and related methods Download PDF

Info

Publication number
AU2022229597A1
AU2022229597A1 AU2022229597A AU2022229597A AU2022229597A1 AU 2022229597 A1 AU2022229597 A1 AU 2022229597A1 AU 2022229597 A AU2022229597 A AU 2022229597A AU 2022229597 A AU2022229597 A AU 2022229597A AU 2022229597 A1 AU2022229597 A1 AU 2022229597A1
Authority
AU
Australia
Prior art keywords
polypeptide
cell
ovarian cancer
subject
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022229597A
Other languages
English (en)
Inventor
Matthew DENT
Nobuyuki Matoba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
University of Louisville Research Foundation ULRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Louisville Research Foundation ULRF filed Critical University of Louisville Research Foundation ULRF
Publication of AU2022229597A1 publication Critical patent/AU2022229597A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022229597A 2021-03-04 2022-03-04 Actinohivin variant polypeptides and related methods Pending AU2022229597A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156715P 2021-03-04 2021-03-04
US63/156,715 2021-03-04
PCT/US2022/070961 WO2022187851A1 (en) 2021-03-04 2022-03-04 Actinohivin variant polypeptides and related methods

Publications (1)

Publication Number Publication Date
AU2022229597A1 true AU2022229597A1 (en) 2023-10-19

Family

ID=83155364

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022229597A Pending AU2022229597A1 (en) 2021-03-04 2022-03-04 Actinohivin variant polypeptides and related methods

Country Status (9)

Country Link
US (1) US20240123026A1 (https=)
EP (1) EP4301389A4 (https=)
JP (1) JP2024509385A (https=)
CN (1) CN117098545A (https=)
AU (1) AU2022229597A1 (https=)
CA (1) CA3210629A1 (https=)
IL (1) IL305259A (https=)
MX (1) MX2023010183A (https=)
WO (1) WO2022187851A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12145966B2 (en) 2017-02-10 2024-11-19 University Of Louisville Research Foundation, Inc. Actinohivin variant polypeptides and methods of treatment using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012071492A1 (en) * 2010-11-23 2012-05-31 Georgia Tech Research Corporation Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells
EP3194973A1 (en) * 2014-09-17 2017-07-26 Institut Curie Map3k8 as a marker for selecting a patient affected with an ovarian cancer for a treatment with a mek inhibitor
US12145966B2 (en) * 2017-02-10 2024-11-19 University Of Louisville Research Foundation, Inc. Actinohivin variant polypeptides and methods of treatment using them

Also Published As

Publication number Publication date
EP4301389A1 (en) 2024-01-10
CN117098545A (zh) 2023-11-21
WO2022187851A9 (en) 2022-09-29
MX2023010183A (es) 2023-11-22
WO2022187851A1 (en) 2022-09-09
CA3210629A1 (en) 2022-09-09
EP4301389A4 (en) 2025-03-12
IL305259A (en) 2023-10-01
JP2024509385A (ja) 2024-03-01
US20240123026A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
AU2019218271B2 (en) Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
JP2022116095A (ja) Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
EP3604338A1 (en) Anti-ox40 antibody and use thereof
WO2020041626A1 (en) Affibody proteins specific for b7-h3 (cd276)
EA022415B1 (ru) Биспецифичные молекулы, связывающие egfr/igfir
WO2012170470A1 (en) Compositions and methods for detection and treatment of cancer
US20200165353A1 (en) Anti-cd22 antigen binding molecules to treat lung cancer and prostate cancer
JP2022081519A (ja) Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
AU2017334698A1 (en) Methods for treating cancer with bavituximab based on levels of β2-glycoprotein 1, and assays therefor
US20210363255A1 (en) Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides
JP7679380B2 (ja) Ｃｄ２７６に特異的な抗体－薬物コンジュゲートおよびその使用
US20240123026A1 (en) Actinohivin Variant Polypeptides and Related Methods
EP2155250B1 (en) Carbohydrate-containing pan cancer marker
JP2023506187A (ja) Ｌｉｖ１－ａｄｃおよびｐｄ－１アンタゴニストとの併用療法
US20250296966A1 (en) Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
WO2015186823A1 (ja) Ｆｏｌｒ１標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬
CN119894929A (zh) 使用PD-1或PD-L1抑制剂和靶向Claudin 18.2的抗体药物偶联物的癌症治疗
CA3203101A1 (en) Actinohivin variant polypeptides and related methods
CA3169521A1 (en) Modified binding polypeptides for optimized drug conjugation
EP4509142A1 (en) Fgfr4 as target in cancer treatment
CN119345386B (zh) 靶向Claudin18.2的抗体药物耦联物及其用途
WO2025088496A1 (en) Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
CN108778274A (zh) 用通过可体内裂解的连接部分与抗蛋白裂解酶抗体缀合的化学治疗剂靶向肿瘤细胞
US20210017288A1 (en) Periostin antibodies and methods of using the same
KR20250021320A (ko) 항-cd228 항체 및 이의 약물 접합체